Publications by authors named "V Ling"
Loss of hepatocyte Usp53 protects mice from a form of xenobiotic-induced liver injury.
Biochim Biophys Acta Mol Basis Dis
December 2024
Background: Ubiquitin-specific protease 53 (USP53) deficiency is associated with familial intrahepatic cholestasis in which serum gamma-glutamyl transferase (GGT) activity is relatively low. However, how USP53 deficiency contributes to cholestasis is obscure. No animal model has been reported.
View Article and Find Full Text PDFBackground: Web-based advance care planning (ACP) interventions offer a promising solution to improve ACP engagement, but none are specifically designed to meet the needs of patients with heart failure and their caregivers.
Objective: We aimed to develop and assess the usability and acceptability of a web-based ACP decision aid called "My Voice," which is tailored for patients with heart failure and their caregivers.
Methods: This study's team and advisory board codeveloped the content for both patient and caregiver modules in "My Voice.
Article Synopsis
- Classical myeloproliferative neoplasms (MPNs) are disorders that originate from stem cells and are marked by specific mutations that activate JAK-signalling pathways, leading to abnormal blood cell production.
- Many patients with MPNs also have additional mutations that can influence the symptoms and worsening of their condition.
- This review explores how these mutations evolve and affect disease progression, discusses the concept of high molecular risk MPN, and suggests ways to use genetic information for better patient management and outcomes.
Background: Supervised consumption service (SCS) use among people who inject drugs may reduce acute care utilization; however, prior studies have been limited by self-reported outcomes and dichotomous exposures.
Methods: We conducted a prospective cohort study using linked questionnaire and health administrative data among people who inject drugs in Toronto, Canada (2018-2020). Baseline SCS use frequency was defined by a participant's self-reported proportion of injections performed at an SCS over the past six months: "all/most" (≥75 %), "some" (26-74 %), "few" (1-25 %), or "none" (0 %).